In combination w/ prednisone or prednisolone for metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after androgen deprivation therapy (ADT) failure in whom chemotherapy is not yet clinically indicated; mCRPC in adult men whose disease has progressed on or after docetaxel-based chemotherapy regimen; in combination w/ prednisone or prednisolone & ADT for patients w/ newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) who may have received up to 3 mth prior to ADT.
HTN, hypokalaemia or fluid retention due to mineralocorticoid excess; decreased bone density. Hypoglycemia. Patients w/ chemotherapy. Patients using prednisone or prednisolone subjected to unusual stress & w/drawal. Patients previously treated w/ ketoconazole. Co-administration of abiraterone & prednisone/prednisolone w/ radium 223 dichloride. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Hepatotoxicity & hepatic impairment. Not to be used in women. Not to be used during pregnancy & lactation.
L02BX03 - abiraterone ; Belongs to the class of other hormone antagonists and related agents. Used in the treatment of metastatic castration-resistant prostate cancer.
Sign Out
